Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer
Abstract
Aim: Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment. Materials & methods: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages. Results: The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887). Conclusion: sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Sundhedsdatastyrelsen. Cancer incidence in Denmark, The Cancer Register 2015 [Nye Kræfttilfælde i Danmark, Cancerregisteret 2015]. www.sundhedsdatastyrelsen.dk.
2.
European Medicines Agency. Annex 1. Summary of product characteristics (Herceptin). Report No.: 15/09/2016. www.ema.europa.eu/ema/.
3.
Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a Phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 13(9), 869–878 (2012).
•• Provides information about the effect and safety of intravenous (iv.) versus subcutaneous (sc.) administration.
4.
Jackisch C, Kim S-B, Semiglazov V et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the Phase III HannaH study. Ann. Oncol. 26(2), 320–325 (2015).
•• Provides updated information about the effect and safety of iv. versus sc. administration.
5.
Danish Breast Cancer Cooperative Group (DBCG). Kvalitetsindikatorrapport for Brystkræft 2015. Landsdækkende Klinisk Kvalitetsdatabase for Brystkræft. Databasernes Fællessekretariat. www.dbcg.dk.
6.
Danish Regions and Municipalities Office for Wage Statistics [Kommunernes og Regionerens Løndatakontor]. www.fldnet.dk/statistik/lpx7/.
7.
Transportøkonomiske Enhedspriser. www.modelcenter.transport.dtu.dk/Noegletal/Transportoekonomiske-Enhedspriser.
8.
Sørensen J. Analysis of differences in resource use and costs for intravenous and subcutaneous administration of Herceptin treatment of HER2-positive breast cancer [Analyse af forskelle i ressourceforbrug og omkostninger ved intravenøs og subkutan administration af Herceptin til behandling af HER2 positiv brystkræft]. University of Southern Denmark, Denmark (2014).
9.
Amgros. Værdisætning af enhedsomkostninger (2017). www.amgros.dk.
10.
Sundhedsdatastyrelsen. Tariffs. 2017 [Takstsystem. Vejledning. 2017] (2017). www.drg.dk.
11.
Jakobsen M, Rasmussen SR, Kjelberg J. Differences in costs of administration of biologics – a case study within gastroenterology [Forskelle i omkostninger ved administrering af biologiske lægemidler – Et casestudie inden for gastroenterologien]. KORA (2015). www.kora.dk/media/3887491/10724_administrering_biologiske_laegemidler.pdf.
12.
Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clin. Outcomes Res. 8, 227–233 (2016).
• Information and results from a similar study in an Italian setting.
13.
Olofsson S, Norrlid H, Karlsson E, Wilking U, Ragnarson Tennvall G. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast Edinb. Scotl. 29, 140–146 (2016).
• Information and results from a similar study in a Swedish setting.
14.
Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J. Med. Econ. 17(7), 459–468 (2014).
15.
Pivot X, Gligorov J, Müller V et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 14(10), 962–970 (2013).
•• Provides information about patients’ preferences for sc. and iv. administration.
16.
Pearson S-A, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia – monitoring the effect of an expensive medicine access program. J. Clin. Oncol. 25(24), 3688–3693 (2007).
Information & Authors
Information
Published In
Copyright
© 2017 Future Medicine Ltd.
History
Received: 26 June 2017
Accepted: 27 October 2017
Published online: 4 December 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0048
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Saby George, Maria T. Bourlon, Michael J. Overman, Matt Dixon, Karishma Shelley, Kristen J. Markus, Rachel M. Kewley, Sophie I. Pope, Laurence Albigès, Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective, Cancer Treatment Reviews, 10.1016/j.ctrv.2025.102974, 139, (102974), (2025).
- Amir Abbas Tahami Monfared, Stephanie Barrows, Lindsey Fox, Brittney Herbel, William L. Herring, Alisha Krumbach, Quanwu Zhang, Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer’s Disease: A U.S. Cost Comparison Model, Neurology and Therapy, 10.1007/s40120-025-00790-2, 14, 5, (1863-1888), (2025).
- undefined Tran Thi My Duyen, undefined Nguyen Vu Lan Chi, undefined Pham Tri Dung, undefined Nguyen Thi Thu Thuy, Economic value of subcutaneous versus intravenous trastuzumab administration in the treatment of HER2-positive breast cancer: A systematic review, Tạp Chí Khoa học Trường Đại học Quốc tế Hồng Bàng, 10.59294/HIUJS.VOL.7.2024.686, (61-72), (2024).
- Raquel Aguiar-Ibáñez, Iain Fotheringham, Lalith Mittal, Arthur Sillah, Smit Pathak, Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review, Advances in Therapy, 10.1007/s12325-024-02985-9, 41, 12, (4396-4417), (2024).
- Luciana Castro Garcia Landeiro, Tamie de Camargo Martins, Ruth Bartelli Grigolon, Isabel Monteiro, Joana Bisol Balardin, Eduardo Padilha, Gilberto Amorim, Stephen Stefani, The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review, Frontiers in Pharmacology, 10.3389/fphar.2024.1338546, 15, (2024).
- Elisabetta Munzone, Alessandra Fabi, Giuseppe Buono, Roberta Caputo, Emilia Montagna, Mara Negri, Francesco Nuzzo, Antonella Palazzo, Ida Paris, Luca Conti, Anna Baggi, Jean Marie Franzini, Michelino De Laurentiis, The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients, Drugs & Therapy Perspectives, 10.1007/s40267-023-01038-5, 39, 12, (432-446), (2023).
- Eric C. Barat, Marianne L.E. Arrii, Annaelle Soubieux-Bourbon, Mikaël Daouphars, Rémi Varin, Patrick R. Tilleul, Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting, The Breast, 10.1016/j.breast.2023.103588, 72, (103588), (2023).
- Ana Parra, Claudia Hernández, Laura Prieto-Pinto, Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2023.2249232, 23, 9, (1017-1026), (2023).
- A. M. Alonso Torres, A. G. Arévalo Bernabé, N. Becerril Ríos, M. F. Hellín Gil, J. M. Martínez Sesmero, V. Meca Lallana, Ll. Ramió-Torrentà, A. Rodríguez-Antigüedad, L. Gómez Maldonado, I. Triana Junco, M. Gómez-Barrera, N. Espinoza Cámac, I. Oyagüez, Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain, PharmacoEconomics - Open, 10.1007/s41669-023-00394-2, 7, 3, (431-441), (2023).
- Conor McCloskey, María Toboso Ortega, Sunita Nair, Maria João Garcia, Federico Manevy, A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting, PharmacoEconomics - Open, 10.1007/s41669-022-00361-3, 7, 1, (3-36), (2022).